UCSF ILD Clinical Research
The UCSF ILD Program is actively studying Interstitial Lung Diseases through several clinical research studies.
A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of Nintedanib over 52 weeks in patients with progressive fibrosing Interstitial Lung Disease (Non-IPF)
Interstitial Lung Disease Registry
The Interstitial Lung Disease Registry is a database of the clinical features of patients with interstitial lung disease that allows researchers to better define the characteristics of these diseases, their potential causes, and their natural history. The registry includes demographics, clinical metrics and survey questionnaires. ILDClinicalTrials@ucsf.edu.
Interstitial Lung Disease Blood and Tissue Repository
The Interstitial Lung Disease Blood and Tissue Repository is a collection of serum, plasma, lung fluid, and lung tissue that is linked to the Interstitial Lung Disease Registry. These samples allow researchers to investigate biological mechanisms of disease and relate their findings to clinically important measures like symptom severity and disease progression. Contact at: ILDClinicalTrials@ucsf.edu.
Biomarker Discovery for Novel Drug Development in Idiopathic Pulmonary Fibrosis. Contact at: ILDClinicalTrials@ucsf.edu.
Pulmonary Fibrosis Foundation Registry
A multicenter, national, patient registry and biorepository for patients with Interstitial Lung Disease.
UCSF Sarcoidosis Clinical Research - Epigenetic T-cell Study
This research study will analyze a type of cell that is important to the immune system, called the T cell. We are interested in epigenetic (gene expression-modifying) differences that characterize these T cells in blood and lung in sarcoidosis. Contact at email@example.com or call (415) 476-9637 for more information. Make sure to identify which study you are interested in, and if leaving a voicemail, give the best time and method to contact you.
UCSF Sarcoidosis Clinical Research - Sarc2.0 Study
Currently recruiting for the Sarc2.0 study, an observational study of people with newly diagnosed pulmonary sarcoidosis. Contact at firstname.lastname@example.org or call (415) 476-9637 for more information. Make sure to identify which study you are interested in, and if leaving a voicemail, give the best time and method to contact you.
A multicenter, randomized, double-blind, placebo-controlled trial to evaluate the safety and efficacy of inhaled Treprostinil in subjects with Pulmonary Hypertension due to parenchymal lung disease/ ILD
Combining the anti-fibrotic effects of Pirfenidone with Mycophenolate for treating scleroderma-related Interstitial Lung Disease
Phase II study of safety, tolerability and efficacy of Pirfenidone in patients with Rheumatoid Arthritis Interstitial Lung Disease
Active Studies No Longer Enrolling
A Phase II Randomized, Double-Blind, Placebo Controlled study of GBT440 to evaluate the safety, tolerability, pharmacokinetics and effect on hypoxemia in subjects with Idiopathic Pulmonary Fibrosis.
A Phase II Randomized, Double-Blind, Placebo Controlled Trial to Evaluate the Efficacy of PRM-151 (recombinant human Pentraxin-2) in Subjects with Idiopathic Pulmonary Fibrosis.
ROCHE/GENENTECH LEBRI GB28547
A Phase II, Randomized, Double-Blind, Placebo-Controlled, Study to Assess the Efficacy and Safety of Lebrikizumab in Patients with Idiopathic Pulmonary Fibrosis.
SENSCIS – [Safety and Efficacy of Nintedanib in Systemic SClerosIS]
A Double-Blind, Randomised, Placebo-Controlled Trial Evaluating Efficacy and Safety of Oral Nintedanib Treatment for at least 52 weeks in Patients with 'Systemic Sclerosis associated Interstitial Lung Disease.
An open-label extension trial of the long term safety of oral Nintedanib in patients with Idiopathic Pulmonary Fibrosis (IPF).
Air Pollution: A Prospective Longitudinal Evaluation of Patients with Idiopathic Pulmonary Fibrosis.
A randomized, double-blind, placebo-controlled phase II study to investigate the efficacy and safety of Rociguat (0.5 mg, 1.0 mg, 1.5 mg, 2.0 mg and 2.5 mg TID) in patients with symptomatic pulmonary hypertension associated with idiopathic interstitial pneumonias (IIP).
Safety and Efficacy of A Lysophosphatidic Acid Receptor Antagonist in Idiopathic Pulmonary Fibrosis. A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of the Safety and Efficacy of BMS-986020 in Subjects with Idiopathic Pulmonary Fibrosis (data analysis in progress).
A Treatment Protocol to Allow Patients in the US with Idiopathic Pulmonary Fibrosis Access to Pirfenidone (this treatment has been approved for sale to the public).
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Assess the Efficacy and Safety of GS-6624 in Subjects with Idiopathic Pulmonary Fibrosis (no study results available).
An Open-Label Extension Study of the Long-Term Safety of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis (IPF) (study results not available).
The Role of Microaspiration in Idiopathic Pulmonary Fibrosis. A prospective cohort study in people who have IPF, HP, and healthy controls to determine whether microaspiration plays a role in the cause and progression of IPF.
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study of STX-100 in Idiopathic Pulmonary Fibrosis.
Weighing Risks and benefits of Laparoscopic Anti-Reflux Surgery in Patients with Idiopathic Pulmonary Fibrosis (WRAP-IPF): A Phase II Clinical Trial. Contact at: ILDClinicalTrials@ucsf.edu.